Option chain shows key data for Vigil Neuroscience's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Vigil Neuroscience.

Vigil Neuroscience (NASDAQ:VIGL) Stock, Option Chain

VIGIL NEUROSCIENCE INC

Vigil Neuroscience

Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.

VIGL

Analyst Color

Biotech

News

Health Care

Analyst Ratings

Movers

Trading Ideas

General

Vigil Neuroscience&#39;s VG-3927 Phase 1 trial shows strong safety, 50% sTREM2 reduction, and potential Alzheimer&#39;s treatment; Phase 2 begins Q3 2025.

Vigil Neuroscience&#39;s Alzheimer&#39;s Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3

Vigil Neuroscience reports promising interim results from its Phase 1 trial of VG-3927, showing a strong safety, tolerability, and pharmacokinetic profile in healthy volunteers. The data support continued development of VG-3927 as a potential daily oral therapy for Alzheimer&#39;s disease.

Small Neurodegenerative Disease-Focused Vigil Neuroscience Says Alzheimer&#39;s Candidate Shows Significant Impact On Disease Bimarker

Earnings

Penny Stocks

Small Cap

Markets

APDN

BDSX

Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the notion that the lower the P/E ratio is, the higher the stock value. The reasoning behind this is straightforward — when a stock&#39;s current market price does not adequately reflect its higher earnings, it suggests potential for growth.

Why You Should Bet on 5 Top-Ranked Stocks With Rising P/E

Vigil Neuroscience Inc

Press Releases

Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference

Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update

Vigil Neuroscience to Present at Upcoming Investor Conferences

Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's Disease

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference

Augustine Therapeutics appoints Gerhard Koenig as Chief Executive Officer as Company Prepares to Enter the Clinic

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum

Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

Adicet Bio

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Atossa Therapeutics

Avalo Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Biomea Fusion

Cabaletta Bio

Climb Bio

Caribou Biosciences

CervoMed

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

HilleVax

IGM Biosciences

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

OncoCyte

Regulus Therapeutics

TScan Therapeutics

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

Exicure

Zura Bio Limited - Class A Ordinary shares

Zura Bio

Wedbush

HC Wainwright & Co.

JMP Securities

Morgan Stanley

Mizuho

Comments

Vigil Neuroscience

Vigil Neuroscience (VIGL) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga